# Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

> **NCT00923195** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 4 (actual)

## Conditions studied

- Melanoma
- Skin Cancer

## Interventions

- **DRUG:** MART-1: 26-35(27L) Peptide
- **DRUG:** Montanide ISA 51 VG
- **DRUG:** gp100:154-162 Peptide
- **PROCEDURE:** Radiation
- **DRUG:** Aldesleukin
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **GENETIC:** Anti-gp 100:154 TCR PBL
- **GENETIC:** Anti-MART-1 F5 TCR PBL

## Key facts

- **NCT ID:** NCT00923195
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923195, "Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00923195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*